Gradual Withdrawal of Low-dose Glucocorticoid in Clinically Quiescent Systemic Lupus Erythematosus.

P

Phramongkutklao College of Medicine and Hospital

Status

Completed

Conditions

Systemic Lupus Erythematosus, SLE

Treatments

Behavioral: Glucocorticoid withdrawal group
Behavioral: Glucocorticoid maintenance group

Study type

Interventional

Funder types

Other

Identifiers

NCT06234852
LUCRA001

Details and patient eligibility

About

This study aims compare the flare rate of maintenance versus gradual withdrawal of 5 mg/day prednisone in systemic lupus erythematosus (SLE) patients with clinically quiescent disease.

Full description

Glucocorticoids (GCs) remains the mainstay of treatment in SLE. Prolong used of glucocorticoid can be leading to various organ damage, even in low dose (< 7.5 mg/day). The rational of tapering GCs in SLE who achieve remission or low disease activity is still debated. Recent trial showed the abrupt discontinuation of GCs in sustained clinical remission of SLE increased rate of flare. This study aims compare the flare rate of maintenance versus gradual withdrawal of 5 mg/day prednisone over 24 weeks in systemic lupus erythematosus (SLE) patients with clinically quiescent disease.

Enrollment

20 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged; 20 years
  • Diagnosis of SLE according to Systemic Lupus International Collaborating Clinic (SLICC) classification SLE criteria, 2012.
  • Achieved clinically quiescent SLE defined as cSLEDAI-2K = 0 for at least 6 months.
  • Current treatment regimen including prednisolone 5mg/day. Prednisolone, antimalarials and/or immunosuppressive therapy had to be stable for at least 4 weeks before randomization.

Exclusion criteria

  • Pregnant or pregnancy planning
  • Unable to follow the schedules
  • Overlap with other autoimmune disease, except secondary SjS and APS
  • Co-morbid with any other condition which required prednisolone treatment
  • Documented adrenal insufficiency

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

20 participants in 2 patient groups, including a placebo group

Glucocorticoid maintenance group
Active Comparator group
Description:
Maintenance of 5-mg of prednisolone daily over 24 weeks
Treatment:
Behavioral: Glucocorticoid maintenance group
Glucocorticoid withdrawal group
Placebo Comparator group
Description:
Gradual withdrawal of daily 5-mg prednisolone to daily 0-mg prednisolone over 20-24 weeks
Treatment:
Behavioral: Glucocorticoid withdrawal group

Trial contacts and locations

1

Loading...

Central trial contact

Rattapol Pakchotanon, M.D.; Supasa Niyompanichakarn, M.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems